Trial Profile
Assessment of STELARA (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies in Patients With Psoriatic Arthritis in Standard Health-Care Practice; A Prospective, Observational Cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Tumour necrosis factor inhibitors
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PsaBio
- Sponsors Janssen Pharmaceutica
- 09 Jun 2023 Results of post-hoc analysis safety, effectiveness and treatment persistence in patients < 60 and ≥ 60 years of age receiving ustekinumab over 3 years, published in the Arthritis Research and Therapy.
- 22 Feb 2023 Results of a post-hoc analysis assessing effects of gender on disease characteristics and treatment impact in patients with psoriatic arthritis published in the Rheumatology
- 13 Dec 2022 Results (n=895) assessing the real-world persistence and long term effectiveness of the ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years, published in the Annals of the Rheumatic Diseases.